February 7, 2018 / 11:42 AM / 8 months ago

BRIEF-Sage Therapeutics Receives FDA Breakthrough Therapy Designation For Sage-217

Feb 7 (Reuters) - Sage Therapeutics Inc:

* SAGE THERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR SAGE-217 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

* SAGE THERAPEUTICS INC - SAGE-217 WAS GENERALLY WELL-TOLERATED

* SAGE THERAPEUTICS INC - IN TRIAL, SAGE-217 MET PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below